Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia

PURPOSE: The development of highly effective targeted agents for chronic lymphocytic leukemia offers the potential for fixed-duration combinations that achieve deep remissions without cytotoxic chemotherapy. PATIENTS AND METHODS: This phase II study tested a combination regimen of obinutuzumab, ibru...

全面介紹

Na minha lista:
書目詳細資料
發表在:J Clin Oncol
Main Authors: Rogers, Kerry A., Huang, Ying, Ruppert, Amy S., Abruzzo, Lynne V., Andersen, Barbara L., Awan, Farrukh T., Bhat, Seema A., Dean, Allison, Lucas, Margaret, Banks, Christin, Grantier, Cara, Heerema, Nyla A., Lozanski, Gerard, Maddocks, Kami J., Valentine, Thomas R., Weiss, David M., Jones, Jeffrey A., Woyach, Jennifer A., Byrd, John C.
格式: Artigo
語言:Inglês
出版: American Society of Clinical Oncology 2020
主題:
ORIGINAL REPORTS
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7605394/
https://ncbi.nlm.nih.gov/pubmed/32795224
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00491
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍